BANGKOK: Thailand plans to start human trials on two Covid-19 vaccines via nasal spray by the end of this year after promising results of experiment in mice, a Thai official has said.

The adenovirus vector-based and influenza virus vector-based Covid-19 vaccines were developed by Thailand’s National Center for Genetic Engineering and Biotechnology, said Anan Jongkaewwattana, director of Veterinary Health Innovation and Management Research Group under the center.

After conducting trials in mice, the center planned to start the first phase of human trials by the end of this year, pending approval from the country’s food and drug administration, Anan said.

He said the trials will also test the vaccines’ protection against the Delta variant, adding that the second phase of human trials is scheduled in March 2022, with a target for volume production in mid-2022 if the trials go well. (Xinhua)